Kanjinti

Active Ingredient(s): Trastuzumab-anns
FDA Approved: * June 13, 2019
Pharm Company: * AMGEN INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Kanjinti Overview

Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer.[3][4][5][6] It is specifically used for cancer that is HER2 receptor positive.[3] It may be used by itself or together with other chemotherapy medication.[3] Trastuzumab is given by slow injection into a vein and injection just under the skin.[3]&am...

Read more Kanjinti Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Trastuzumab

Recent Kanjinti Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Trastuzumab-anns
  • Injection: 100mg, 150mg, 420mg, 420mg/vial, 440mg, 600mg + 10000units
  • Vial: 100mg, 150mg, 160mg, 21mg/ml, 420mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Kanjinti: (2 results)

Sorted by National Drug Code
  • 55513-132 Kanjinti 420 mg/20ml Intravenous Injection, Powder, Lyophilized, for Solution by Amgen Inc
  • 55513-141 Kanjinti 150 mg/7.15ml Intravenous Injection, Powder, Lyophilized, for Solution by Amgen Inc

Other drugs which contain Trastuzumab-anns or a similar ingredient: (12 results)